Verastem, Inc.VSTM

Verastem Oncology’s 10-Q for the quarter ended 31 March 2026 lands with a thud: $18.7 million in revenue, a $36.6 million net loss, and $52.1 million of operating cash used, all while the company’s cash and equivalents stood at $165.6 million and short-term investments at $16.1 million. The filing also reports negative shareholders’ equity of $81.8 million against liabilities of $146.0 million, numbers that sit awkwardly beneath the company’s polished product graphics and clinical-trial promises. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1526119/000197415826000087/000197415826000087-10q.htm)

On the same day the numbers landed, Verastem’s 8-K dated 23 June 2026 announced a collaboration with Erasca to co-develop two oncology programmes, a headline that understandably dominated investor decks even as the cash-flow line item quietly explained why collaboration announcements rarely arrive on quarters when the company is self-funding its burn. The collaboration press release itself sits on the company’s contact page, where the product information centre directs clinicians and partners to a toll-free oncology line and an adverse-event email inbox-touchpoints that feel more like triage than commercial traction. (source: 8-K, 2026-06-23, https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/tm2618546d1_8k.htm; contact page https://www.verastem.com/contact-us/)

The company’s pipeline page insists it is changing the calculus for patients with difficult-to-treat cancers, yet the same filing shows $38.2 million poured into research and development in the quarter and inventory rising by $454,000 to $2.3 million-hardly the picture of a near-commercial asset ready to sell. Earnings per share came in at a diluted $-0.46 on 99.1 million shares, a metric that matters more when the company’s weighted average diluted share count is rising even as the burn continues. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1526119/000197415826000087/000197415826000087-10q.htm)

SEC filings this week include two Form 144 notices (25 June and 23 July 2026) detailing restricted share sales by officers and directors, a disclosure rhythm that keeps dilution risk alive even as the company’s 13G/A filing on 8 July shows a passive investor edging toward a 9.9% stake. The optics are textbook small-cap theatre: a website still draped in oncology promise, a balance sheet still counting the cost of science, and a register where restricted sales and secondary filings do the talking long before any product does. (source: 144, 2026-06-25, https://www.sec.gov/Archives/edgar/data/1526119/000197415826000075/xsl144X01/primary_doc.xml; 144, 2026-07-23, https://www.sec.gov/Archives/edgar/data/1526119/000197415826000089/xsl144X01/primary_doc.xml; 13G/A, 2026-07-08, https://www.sec.gov/Archives/edgar/data/1526119/000117266126002511/xslSCHEDULE_13G_X02/primary_doc.xml)

For readers who like their biotech with a side of disclosure theatre, the company’s clinical-trials rail offers upbeat pipeline graphics and trial identifiers, while the balance sheet keeps its own ledger of cash-burn and inventory build. The tension between promise and proof is not a bug; it is the filing itself. (source: clinical trials page https://www.verastem.com/our-science/clinical-trials/)